Multiple Sclerosis Pill (Laquinimod ) Reduced Brain Lesions in Trial
Posted Jan 14 2009 8:24pm
Teva's Multiple Sclerosis Pill Reduced Brain Lesions in Trial
By Alex Kuli
June 20 (Bloomberg) -- Teva Pharmaceutical Industries Ltd.'sexperimental multiple sclerosis pill helped reduce brain lesions in a new study, moving the Israeli drugmaker closer to introducing the first oral treatment for the disabling disease.
Patients with the relapsing-remitting form of the illness on a daily dose of the medicine, laquinimod, had 40 percent fewer brain lesions than those on a placebo, according to the study in The Lancet medical journal. Lesions are caused when the immune system attacks the fatty tissue around nerve fibers, breaking the connection between brain and muscle.